Helicobacter pylori treatment: A role for probiotics?

Filippo Cremonini, Filippo Canducci, Simona Di Caro, Luca Santarelli, Alessandro Armuzzi, Giovanni Gasbarrini, Antonio Gasbarrini

Research output: Contribution to journalArticle

Abstract

Many new therapeutic strategies are studied to improve Helicobacter pylori eradication rate. Probiotics are live microorganisms which, upon administration, may interact with the human microflora and positively affect the health status. The use of probiotics in the field of H. pylori infection has been proposed for improving eradication rate and tolerability and for compliance of multiple antibiotic regimens used for the infection. Results from laboratory studies and from clinical trials seem to confirm the expectancies, but there is lack of standardization in terms of type of probiotic strain used, dosage and timing of supplementation. Before further ongoing trials and future studies will clarify these points, probiotics could remain a useful adjunct to standard anti-H. pylori therapies, but cannot take the place of other validated options.

Original languageEnglish
Pages (from-to)144-147
Number of pages4
JournalDigestive Diseases
Volume19
Issue number2
DOIs
Publication statusPublished - 2001

Fingerprint

Probiotics
Helicobacter pylori
Helicobacter Infections
Health Status
Compliance
Clinical Trials
Anti-Bacterial Agents
Therapeutics
Infection

Keywords

  • Helicobacter pylori
  • Lactobacillus
  • Probiotics

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Cremonini, F., Canducci, F., Di Caro, S., Santarelli, L., Armuzzi, A., Gasbarrini, G., & Gasbarrini, A. (2001). Helicobacter pylori treatment: A role for probiotics? Digestive Diseases, 19(2), 144-147. https://doi.org/10.1159/000050669

Helicobacter pylori treatment : A role for probiotics? / Cremonini, Filippo; Canducci, Filippo; Di Caro, Simona; Santarelli, Luca; Armuzzi, Alessandro; Gasbarrini, Giovanni; Gasbarrini, Antonio.

In: Digestive Diseases, Vol. 19, No. 2, 2001, p. 144-147.

Research output: Contribution to journalArticle

Cremonini, F, Canducci, F, Di Caro, S, Santarelli, L, Armuzzi, A, Gasbarrini, G & Gasbarrini, A 2001, 'Helicobacter pylori treatment: A role for probiotics?', Digestive Diseases, vol. 19, no. 2, pp. 144-147. https://doi.org/10.1159/000050669
Cremonini F, Canducci F, Di Caro S, Santarelli L, Armuzzi A, Gasbarrini G et al. Helicobacter pylori treatment: A role for probiotics? Digestive Diseases. 2001;19(2):144-147. https://doi.org/10.1159/000050669
Cremonini, Filippo ; Canducci, Filippo ; Di Caro, Simona ; Santarelli, Luca ; Armuzzi, Alessandro ; Gasbarrini, Giovanni ; Gasbarrini, Antonio. / Helicobacter pylori treatment : A role for probiotics?. In: Digestive Diseases. 2001 ; Vol. 19, No. 2. pp. 144-147.
@article{7492a7ae1091457c929bccf2f09558af,
title = "Helicobacter pylori treatment: A role for probiotics?",
abstract = "Many new therapeutic strategies are studied to improve Helicobacter pylori eradication rate. Probiotics are live microorganisms which, upon administration, may interact with the human microflora and positively affect the health status. The use of probiotics in the field of H. pylori infection has been proposed for improving eradication rate and tolerability and for compliance of multiple antibiotic regimens used for the infection. Results from laboratory studies and from clinical trials seem to confirm the expectancies, but there is lack of standardization in terms of type of probiotic strain used, dosage and timing of supplementation. Before further ongoing trials and future studies will clarify these points, probiotics could remain a useful adjunct to standard anti-H. pylori therapies, but cannot take the place of other validated options.",
keywords = "Helicobacter pylori, Lactobacillus, Probiotics",
author = "Filippo Cremonini and Filippo Canducci and {Di Caro}, Simona and Luca Santarelli and Alessandro Armuzzi and Giovanni Gasbarrini and Antonio Gasbarrini",
year = "2001",
doi = "10.1159/000050669",
language = "English",
volume = "19",
pages = "144--147",
journal = "Digestive Diseases",
issn = "0257-2753",
publisher = "S. Karger AG",
number = "2",

}

TY - JOUR

T1 - Helicobacter pylori treatment

T2 - A role for probiotics?

AU - Cremonini, Filippo

AU - Canducci, Filippo

AU - Di Caro, Simona

AU - Santarelli, Luca

AU - Armuzzi, Alessandro

AU - Gasbarrini, Giovanni

AU - Gasbarrini, Antonio

PY - 2001

Y1 - 2001

N2 - Many new therapeutic strategies are studied to improve Helicobacter pylori eradication rate. Probiotics are live microorganisms which, upon administration, may interact with the human microflora and positively affect the health status. The use of probiotics in the field of H. pylori infection has been proposed for improving eradication rate and tolerability and for compliance of multiple antibiotic regimens used for the infection. Results from laboratory studies and from clinical trials seem to confirm the expectancies, but there is lack of standardization in terms of type of probiotic strain used, dosage and timing of supplementation. Before further ongoing trials and future studies will clarify these points, probiotics could remain a useful adjunct to standard anti-H. pylori therapies, but cannot take the place of other validated options.

AB - Many new therapeutic strategies are studied to improve Helicobacter pylori eradication rate. Probiotics are live microorganisms which, upon administration, may interact with the human microflora and positively affect the health status. The use of probiotics in the field of H. pylori infection has been proposed for improving eradication rate and tolerability and for compliance of multiple antibiotic regimens used for the infection. Results from laboratory studies and from clinical trials seem to confirm the expectancies, but there is lack of standardization in terms of type of probiotic strain used, dosage and timing of supplementation. Before further ongoing trials and future studies will clarify these points, probiotics could remain a useful adjunct to standard anti-H. pylori therapies, but cannot take the place of other validated options.

KW - Helicobacter pylori

KW - Lactobacillus

KW - Probiotics

UR - http://www.scopus.com/inward/record.url?scp=0034846597&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034846597&partnerID=8YFLogxK

U2 - 10.1159/000050669

DO - 10.1159/000050669

M3 - Article

C2 - 11549824

AN - SCOPUS:0034846597

VL - 19

SP - 144

EP - 147

JO - Digestive Diseases

JF - Digestive Diseases

SN - 0257-2753

IS - 2

ER -